Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Fractures, Bone 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Carboplatin 6Paclitaxel 4Therapeutics 2Taxes 2saracatinib 1rubitecan 1romidepsin 1epacadostat 1Toremifene 1Surveys and Questionnaires 1Radiotherapy 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Pentetic Acid 1Palliative Care 1Ovariectomy 1N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea 1Minocycline 1Methods 1Metformin 1Hyperthermic Intraperitoneal Chemotherapy 1Heparin 1Gene Expression Profiling 1Gemcitabine 1Early Intervention, Educational 1Doxorubicin 1Depsipeptides 1Cisplatin 1Celecoxib 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Ovarian Epithelial × Toremifene × Clear all
NCT00003865 2017-07-13

Toremifene in Treating Patients With Ovarian Cancer

George Washington University

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡